Editorial: ADAM, ADAMTS and Astacin Proteases: Challenges and Breakthroughs in the -Omics Era
Kazuhiro Yamamoto
Rens de Groot2 
Simone Dario Scilabra
Hang Fai Kwok
Salvatore Santamaria- 1Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom
- 2Institute of Cardiovascular Science, University College London, London, United Kingdom
- 3Proteomics Group of Fondazione Ri.MED, Department of Research IRCCS ISMETT, Palermo, Italy
- 4Cancer Centre, Faculty of Health Sciences, University of Macau, Macau, China
- 5MOE Frontiers Science Center for Precision Oncology, University of Macau, Macau, China
- 6Department of Immunology and Inflammation, Imperial College London, London, United Kingdom
Editorial on the Research Topic
ADAM, ADAMTS and Astacin Proteases: Challenges and Breakthroughs in the -Omics Era
Metzincins are a superfamily of metalloproteinases characterized by the presence of a conserved methionine residue downstream the active site zinc (Cerdà-Costa and Gomis-Rüth, 2014). This Frontiers Research Topic is focused on three metzincin sub-families: ADAMs (A Disintegrin and Metalloproteinases), ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin motifs) and Astacins. Research into these proteases has seen impressive breakthroughs thanks to the progress of the -Omics era. Genome Wide Association Studies (GWAS) have implicated several ADAM and ADAMTS family members in human disease, for example ADAMTS7 in Coronary Artery Disease (Reilly et al., 2011), and ADAM10 in Alzheimer’s disease (Marioni et al., 2018; Schwartzentruber et al., 2021). Although less characterized, the proteolytic activity of Astacins has been linked to digestion, cytokine activation and cancer (Sterchi et al., 2008; Peters and Becker-Pauly, 2019).
ADAMTSs are a family of 19 secreted proteases playing a crucial role in the turnover of the extracellular matrix (ECM). While a fine regulation of their activity ensures tissue homeostasis, several pathological conditions are associated with their aberrant activity. Rose et al. comprehensively review the current knowledge about regulatory mechanisms of ADAMTS activity. Protein levels and activity of ADAMTSs can be modulated at different levels, including transcriptional regulation, alternative splicing, proteolytic activation, endocytosis, and inhibition by tissue inhibitors of metalloproteinases (TIMPs). A deeper understanding of such regulatory mechanisms can lead to new strategies to target the pathological potential of specific ADAMTSs without affecting the physiological activity of other family members. The contribution by Jiang et al. provides updated insights on multiple layers of regulation of one of the best characterized ADAMTS family members, ADAMTS5. ADAMTS5 is an important pharmaceutical target in osteoarthritis (OA) due to its ability to cleave aggrecan, the major proteoglycan in articular cartilage (Santamaria, 2020). Since no disease-modifying OA therapies are currently available, the authors summarize current preclinical approaches to target ADAMTS5. Monoclonal antibodies and small molecule inhibitors against ADAMTS5 were proved to be beneficial pre-clinically. Based on the recent novel RNA therapies that demonstrated potential in OA animal models, the authors emphasize that upstream signaling blockade of ADAMTS5 using mi/siRNAs may represent a feasible therapeutic strategy for OA.
ADAMTS12 is another example of how we are just starting to scratch the surface of ADAMTS complexity. Mohamedi et al. overview this complex and multifunctional metalloproteinase on the 20th anniversary of its identification. The authors discuss functions of ADAMTS12 in inflammatory processes, arthritis, degenerative intervertebral disc, chondrogenesis, tendon degeneration, cancer, neurological and fertility disorders. Different domains of ADAMTS12 can interact with different ECM components, which in turn modify its proteolytic activity. The authors emphasize that identification of ADAMTS12-binding partners would contribute to a deeper understanding of its biological functions.
A central aspect of this Research Topic is the identification of novel metzincin substrates using state-of-the-art proteomics approach. In the last decade, mass spectrometry-based techniques have dramatically expanded our knowledge of proteases’ substrate repertoire, the degradome (López-Otín and Overall, 2002). The most successful techniques have been those targeting the newly formed N-terminus generated following cleavage of the substrate, such as N-Terminal Amine Isotopic Labeling of Substrates (TAILS) (Mintoo et al., 2021). N-TAILS has been instrumental to elucidate the degradome of ADAMTS7 (Colige et al., 2019), 2, 3, and 14 (Bekhouche et al., 2016). While these approaches used fibroblast conditioned media as a source of substrates, Leduc et al. investigated substrates in vivo by directly comparing skin from Adamt2−/−, Adamts14−/− and Adamts2−/−/Adamts14−/− knockout mice with those of wild type littermates. Their results confirm the cleavage site preference (P1 and P1′ residues) of these proteases and provide more detail about their role in collagen fibril organization. As often in proteomics, further studies are required to assess the relevance of these intriguing proteolytic events and novel substrates.
The current pandemic has stressed the need for better intervention strategies aiming at the prevention and treatment of infections caused by respiratory viruses. As highlighted by Pedrina and Stambas, the ECM offers novel opportunities for intervention. The proteoglycan versican is a major ECM component and has been shown to be involved in the immune response to viral infection by binding chemokines that guide leukocyte extravasation. Versican also provides a barrier for leukocyte migration, as summarized in the contribution by McMahon et al. ADAMTS4 and ADAMTS5 are the two major versicanases (Santamaria et al., 2019), so it does not come as a surprise that they have been implicated in the pathological ECM remodeling that occurs upon viral infection. However, their role seems to be radically different. ADAMTS5 versicanase activity seems to exert a beneficial role by facilitating leucocyte migration as demonstrated by the delayed virus clearance observed in Adamts5 knockout mice (McMahon et al., 2016). On the other hand, ADAMTS4 expression positively correlates with severe influenza virus infection in humans (Boyd et al., 2020), suggesting that ADAMTS4 can be a potential target for therapeutic intervention. Several inhibitory antibodies have been described (Santamaria and de Groot, 2019) and these can be deployed to target ADAMTS4 and other metzincins involved in the dysregulated immune response to viral infection. On the other hand, increasing the activity of ADAMTS5 in the context of severe influenza infection may not be trivial. Although increased ADAMTS5 activity has been achieved indirectly by blocking its endocytosis with a monoclonal antibody (Santamaria et al., 2017), a caveat when considering ADAMTSs as therapeutic targets is their complex, multisystemic role, for example their involvement in cardiovascular homeostasis (Santamaria and de Groot, 2020).
Like ADAMs, Astacins can cleave membrane-tethered proteins and therefore act as sheddases (Sterchi et al., 2008; Peters and Becker-Pauly, 2019). Meprin β is perhaps the best characterized Astacin. Meprin β is a type I transmembrane protein whose expression is associated with certain types of cancer, including melanoma. Thus, it is crucial to find the driver mutation(s) of meprin β and its variants to study the impact on the invasiveness of tumor cells. Two genetic variants of meprin β (G45R and G89R) have been found in melanomas. Gellrich et al. characterized these two variants and found that, similar to wild type meprin β, the G45R variant is able to shed a number of specific substrates and promote invasion when expressed in HeLa cancer cells. On the other hand, the G89R variant showed impaired trafficking to the cell surface, reduced shedding of its target substrates and diminished cancer cell invasion. A similar mechanistic approach can be extended to elucidate the activity of other meprin β variants (Peters and Becker-Pauly, 2019).
Overall, the studies included in this Research Topic expand our knowledge of the role and regulation of ADAMs, ADAMTSs and Astacins in a variety of biological processes, something that would not have been possible without the powerful new -Omics tools that have been widely adopted in the last decade.
Author Contributions
KY, RdG, SDS, HK and SS planned, wrote, and revised the editorial manuscript. All authors contributed to the article and approved the submitted version.
Funding
The work of the authors is supported by funds from the Versus Arthritis (21447 to KY), the Fondazione con il Sud within the “Brains to South” program (Grant Agreement No. 2018–PDR–00799 to SDS), the Science and Technology Development Fund of Macau SAR (FDCT) (0055/2019/A1 to HK) and the British Heart Foundation (FS/IBSRF/20/25032 to SS).
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Bekhouche, M., Leduc, C., Dupont, L., Janssen, L., Delolme, F., Goff, S. V. L., et al. (2016). Determination of the Substrate Repertoire of ADAMTS2, 3, and 14 Significantly Broadens Their Functions and Identifies Extracellular Matrix Organization and TGF‐β Signaling as Primary Targets. FASEB j. 30 (5), 1741–1756. doi:10.1096/fj.15-279869
Boyd, D. F., Allen, E. K., Allen, E. K., Randolph, A. G., Guo, X.-z. J., Weng, Y., et al. (2020). Exuberant Fibroblast Activity Compromises Lung Function via ADAMTS4. Nature 587 (7834), 466–471. doi:10.1038/s41586-020-2877-5
Cerdà-Costa, N., and Gomis-Rüth, X. F. (2014). Architecture and Function of Metallopeptidase Catalytic Domains. Protein Sci. 23 (2), 123–144. doi:10.1002/pro.2400
Colige, A., Monseur, C., Crawley, J. T. B., Santamaria, S., and de Groot, R. (2019). Proteomic Discovery of Substrates of the Cardiovascular Protease ADAMTS7. J. Biol. Chem. 294 (20), 8037–8045. doi:10.1074/jbc.RA119.007492
López-Otín, C., and Overall, C. M. (2002). Protease Degradomics: a New challenge for Proteomics. Nat. Rev. Mol. Cell Biol 3 (7), 509–519. doi:10.1038/nrm858
Marioni, R. E., Harris, S. E., Zhang, Q., McRae, A. F., Hagenaars, S. P., Hill, W. D., et al. (2018). GWAS on Family History of Alzheimer’s Disease. Transl Psychiatry 8 (1), 99. Erratum in: Transl Psychiatry. (2019); 9(1):161. doi:10.1038/s41398-018-0150-6
McMahon, M., Ye, S., Izzard, L., Dlugolenski, D., Tripp, R. A., Bean, A. G. D., et al. (2016). ADAMTS5 Is a Critical Regulator of Virus-specific T Cell Immunity. Plos Biol. 14 (11), e1002580. doi:10.1371/journal.pbio.1002580
Mintoo, M., Chakravarty, A., and Tilvawala, R. (2021). N-terminomics Strategies for Protease Substrates Profiling. Molecules 26 (15), 4699. doi:10.3390/molecules26154699
Peters, F., and Becker-Pauly, C. (2019). Role of Meprin Metalloproteases in Metastasis and Tumor Microenvironment. Cancer Metastasis Rev. 38 (3), 347–356. doi:10.1007/s10555-019-09805-5
Reilly, M. P., Li, M., He, J., Ferguson, J. F., Stylianou, I. M., Mehta, N. N., et al. (2011). Identification of ADAMTS7 as a Novel Locus for Coronary Atherosclerosis and Association of ABO with Myocardial Infarction in the Presence of Coronary Atherosclerosis: Two Genome-wide Association Studies. The Lancet 377 (9763), 383–392. doi:10.1016/S0140-6736(10)61996-4
Santamaria, S. (2020). ADAMTS‐5: A Difficult Teenager Turning 20. Int. J. Exp. Path. 101 (1-2), 4–20. doi:10.1111/iep.12344
Santamaria, S., and de Groot, R. (2020). ADAMTS Proteases in Cardiovascular Physiology and Disease. Open Biol. 10 (12), 200333. doi:10.1098/rsob.200333
Santamaria, S., and de Groot, R. (2019). Monoclonal Antibodies against Metzincin Targets. Br. J. Pharmacol. 176 (1), 52–66. doi:10.1111/bph.14186
Santamaria, S., Fedorov, O., McCafferty, J., Murphy, G., Dudhia, J., Nagase, H., et al. (2017). Development of a Monoclonal Anti-ADAMTS-5 Antibody that Specifically Blocks the Interaction with LRP1. MAbs 9 (4), 595–602. doi:10.1080/19420862.2017.1304341
Santamaria, S., Yamamoto, K., Teraz-Orosz, A., Koch, C., Apte, S. S., de Groot, R., et al. (2019). Exosites in Hypervariable Loops of ADAMTS Spacer Domains Control Substrate Recognition and Proteolysis. Sci. Rep. 9 (1), 10914. doi:10.1038/s41598-019-47494-w
Schwartzentruber, J., Cooper, S., Liu, J. Z., Barrio-Hernandez, I., Bello, E., Kumasaka, N., et al. (2021). Genome-wide Meta-Analysis, fine-mapping and Integrative Prioritization Implicate New Alzheimer’s Disease Risk Genes. Nat. Genet. 53 (3), 392–402. doi:10.1038/s41588-020-00776-w
Keywords: ADAM, ADAMTS, proteomics, extracellar matrix, astacin
Citation: Yamamoto K, de Groot R, Scilabra SD, Kwok HF and Santamaria S (2021) Editorial: ADAM, ADAMTS and Astacin Proteases: Challenges and Breakthroughs in the -Omics Era. Front. Mol. Biosci. 8:780242. doi: 10.3389/fmolb.2021.780242
Received: 20 September 2021; Accepted: 23 September 2021;
Published: 12 October 2021.
Edited and reviewed by:
Andrea Mozzarelli, University of Parma, ItalyCopyright © 2021 Yamamoto, de Groot, Scilabra, Kwok and Santamaria. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Salvatore Santamaria, s.santamaria@imperial.ac.uk